Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTREAT: Envarsus for Impaired Glucose Tolerance Post Renal Transplant
NCT04973982Withdrawn
- Sponsor
- Barts Health NHS Trust
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Randomised, open-label trial of tacrolimus in impaired glucose tolerance (IGT), sponsored by Barts Health NHS Trust. Primary endpoint: Proportion of patients who normalise their impaired glucose tolerance at 3 months. Planned start Jan 2022; status: withdrawn.
02
Drugs
tacrolimus
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT04973982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973982.